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INTRODUCTION
Although a great deal of effort was put into the develop-
ment of xenografts and homografts in Korea between 1970-
1980 (1, 2), no successful experiments with these techniques
has been reported. During this period, O’Brien and colleagues
reported the standardization of a homograft cryopreservation
approach (3). This approach was also used in clinical practice.
Homografting, though it had many benefits and resulted
in superior outcomes compared to xenografting, also had
many limitations, including early calcification, immuno-
logic rejection, and generally poor durability. Due to these
limitations, research into xenograft-related immunosuppres-
sion emerged as another target of research. The Toronto group
reported a wide variety of outcomes from immunosuppres-
sion via the removal of the xenograft’s antigens (4). Bader et
al., as well as Teebken et al. also reported that the endotheli-
um of the recipient could be repopulated into the acellular-
ized xenograft (5, 6).
We hypothesized that xenografts in which the antigens
had been removed (especially the endothelial variety), might
exhibit less pronounced immunological rejection character-
istics than other varieties of xenografts. In acellular xeno-
grafts, repopulation with the recipient’s endothelium might
also be conducted, showing possibilities of the production
of a practically acceptable xenograft. 
Although many studies have been conducted and reported
good results under these hypotheses, we wanted to improve
the acellularizing processes, especially in the process of nucle-
ase treating and the removal of phospholipids to prevent the
calcification of xenografts, to make more ideal xenografts.
MATERIALS AND METHODS
Materials 
We used the left subclavian arteries of pigs (weighing bet-
ween 200-250 kg, cadaveric donors) in the construction of
xenografts. Mongrel dogs, weighing between 20-25 kg, were
employed as recipients. This study was approved by the Insti-
tutional Animal Care and Use Committee of Korea Univer-
sity. The animal care conducted throughout this study was
consistent with the guidelines and rules of the Guide for the
Care and Use of Laboratory Animals.
All chemical reagents and buffers, unless stated otherwise,
were obtained from the SIGMA Chemical Company (St.
Louis, Mo, U.S.A.).
Acellular matrix (de-endothelialization) processing
The processes by which the de-endothelialization of the
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Modified Acellularization for Successful Vascular Xenotransplantation
The purpose of this study was to estimate the possibilities of an acellular matrix using
a modified acellularization protocol, which circumvents immunological, microbiologi-
cal, and physiological barriers. We treated porcine subclavian arteries with various
reagents to construct acellular grafts. Afterwards, these grafts were interposed in a
mongrel dogs’ abdominal aorta. Six dogs underwent interposition with fresh porcine
grafts (control group), and seven had interposed acellular grafts (acellular group).
The control and acellular group dogs were sacrificed at 1, 3, 5 (n=2 in each group)
and 12 months (n=1 in acellular group) after the operation. Histopathological exami-
nations were then performed, to assess the degree to which re-endothelialization,
inflammation, thrombus formation, and calcification occurred. The entire acellular
group, but none of the control group, exhibited re-endothelialization. The degrees
to which inflammation, thrombosis, and calcification occurred were found to be lower
in the acellular group. We also discovered many smooth muscle cells in the medi-
al layer of the xenograft that had been implanted in the dog sacrificed 12 months
after the operation. These results suggest that the construction of xenografts using
our modified acellularization protocol may offer acceptable outcomes as a vascular
xenograft. 
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porcine left subclavian artery were based on the methods
developed in several previous reports (7). The construction
of a viable biological matrix for the xenograft requires the
depletion of cellular antigens, and the maintenance of the
matrix for subsequent tissue repopulation. 
First, about 3 cm of the left subclavian artery of the pig
was resected in a slaughter house, after which debridement
and trimming were performed aseptically. Then, the tissue
was taken to a laboratory in an aseptic bottle filled with a
phosphate buffer solution (pH 7.0) (8). After trimming and
cleansing, the graft was treated with hypotonic Tris buffer
solution (TBS, pH 8.0). This facilitated the loosening of the
original tissue cells. It is important, in this step, not to allow
overly aggressive proteolytic degradation that may destroy
the entire matrix, including the collagen that comprises much
of its structural integrity. A protease inhibitor, phenylmethyl-
sulfonyl fluoride (PMSF, 0.35 mL/L), was used to control pro-
tease activity (4, 7). Following this procedure, the damaged
or destroyed cellular debris, nuclease, and other enzymes were
washed and deactivated using Hanks’ balanced salt solution
(HBSS) (4, 7, 9). Then, the xenografts were treated with alky-
lphenoxypolyethoxyethanol (Triton-X 100; nonionic deter-
gent) along with TBS and PMSF. Triton-X 100, which des-
troys the cellular membrane and removes floating materials
(4, 7, 10), was applied. After 24 hr of HBSS treatment at 4℃,
the tissue was treated with nuclease. Nuclease digests the
DNA, RNA, and exonuclease in the native cells without col-
lagen lysis. We selected DNAase I (1.0  g/mL) and a RNAase
A (1.0  g/mL) as our experimental nucleases for this step (4,
7, 11). The nuclease reaction time was set for 2 hr, based on
several of the authors’ preliminary experiences with such pro-
cedures. After the nuclease treatment, the tissue was retreated
with HBSS, TBS, and Triton-X 100 for the next 24 hr (4℃).
One-percent sodium dodecyl sulfate (SDS), a detergent, was
applied in order to effect the selective solution of the remain-
ing cellular membrane, and to selectively remove phospho-
lipids from the tissue (12, 13). The removal of the phospho-
lipids and cellular materials was important for the prevention
of xenograft calcification (9, 14, 15). One-percent SDS was
allowed to react in a 2-Hydroxyethypiperazine N-2-ethansul-
fonic acid (HEPES) buffer solution (pH 7.4) for at least 19 hr.
This section of the procedure was also set up according to
the results of several of the authors’ preliminary experiences
with this procedure.
The summarized protocol for acellular matrix processes is
shown in Table 1.
Methods for the confirmation of the acellular matrix
We conducted histopathological examinations of the xeno-
graft as an acellular matrix, using light microscopy and elec-
tron microscopy. Unfortunately we could not show the data
of the mechanical properties, so we defined acellular matrix
as an absolute absence of cellular materials (not collagenic
matrix) in histopathological examination.
Operation methods
Anesthetic induction was conducted using ketamin (40
mg/kg, i.m) and propofol (1.5 mg/kg, i.v). After endotracheal
intubation, 3% isofluorane was used to maintain anesthesia.
Mechanical ventilation with 100% oxygen was then conduct-
ed, blood pressure was monitored through the femoral artery,
and EKG tests were performed. Each recipient animal under-
went a left abdominal horizontal incision along the spine, and
the abdominal aorta was dissected via a retroperitoneal app-
roach. Aortic clamping was conducted proximally and dis-
tally to the abdominal aorta at sites with no branches, result-
ing in an operation field of approximately 4-5 cm. The 3 cm
length of the xenograft was interposed. The canines’ average
aortic diameter was 1.36±0.16 cm, which was almost half
of the xenograft’s diameter, at 2.63±1.50 cm. Therefore, it
was necessary to reduce the diameter of the xenograft.
The de-cellularized xenografts were transplanted to the
abdominal aorta (20-25 kg) of each of the 7 dogs in the acel-
lular group, and fresh untreated xenografts were transplant-
ed to another six dogs, which comprised the control group.
In order to minimize the interference of external factors
in this study, we used no antibiotics in this procedure, except
at the beginning of induction and the end of the operation.
No anticoagulants or immunosuppressants were used through-
out the study period. The donors (pig) and recipients (dog)
were all raised in a general environment, rather than an asep-
tic environment.
Histopathological examinations after operation
Many authors reported the ingrowth of endothelial cells
and smooth muscle actin positive cells into the de-endothe-
lialized xenograft (repopulation) by 2 month to 11 months
TBS, Hypotonic Tris buffer; PMSF, Phenylmethyl-sulfonyl fluoride; HBSS,
Hanks’ balanced salt solution; HEPES, 2-Hydroxyethypiperazine N-2-
ethansulfonic acid; SDS, Sodium dodecyl sulfate.
1) Donor subclavian artery harvesting & trimming
2) TBS (pH 8.0)+PMSF (0.35 mL/L, 4°C, 24 hr stirring)
3) Rinsing in HBSS (4°C 2 hr stirring) 
4) TBS+Triton-x 100 (alkylphenoxypolyethoxyethanol)+PMSF 
(4°C 24 hr stirring)
5) Rinsing in HBSS (4°C 24 hr stirring) 
6) Digestion with DNAase I (1.0  g/mL) and RNAase A (1.0  g/mL) 
(37°C, 2 hr)
7) Rinsing in HBSS (4°C 24 hr stirring) 
8) TBS (pH 8.0)+Triton-x 100 (alkylphenoxypolyethoxyethanol )
(4°C 24 hr stirring)
9) Rinsing in HBSS (4°C 24 hr stirring) 
10) HEPES (pH 7.4)+1% SDS (19 hr)
11) Fixed solution
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(16-18) after implantation. Elkins and colleagues, especially,
reported as much as 80% repopulation of donor cells into
decellularized xenograft by 11 months after implantation
(18). We, therefore, conducted histopathological studies at
1, 3, 5 (n=2 in control and acellular groups) and 12 months
(n=1 in acellular group) after the initial operation. 
During the histopathological studies, we compared the
degrees to which re-endothelialization, inflammation, throm-
bus formation, and calcification occurred in each group, via
hematoxylin and eosin staining. 
The re-endothelialization of the recipient’s endothelium
to the decellularized xenograft was identified via immuno-
histochemical staining with rabbit anti-human factor VIII
antibody (DAKO, Inc, Japan). We found that Rabbit Anti-
human Factor VIII Antibody reacted with canine endothe-
lium, but not porcine endothelium, which was consistent with
the authors’ preliminary experiences (Fig. 1). 
The degrees of inflammation was measured according to the
depth of invasion of the inflammatory cells from the adventia
of the xenograft with a 100 scale (=1 cm) microscopic ruler.
The degrees of the calcification and thrombus formation were
also graded according to a calcified graft length/whole graft
Fig. 1. Endothelial cells of cellular matrix. (A) Dog aorta (hematoxylin and eosin stain). (B) Pig graft (hematoxylin and eosin stain). (C) Immu-
nohistochemical staining of dog aorta with rabbit anti-human Factor VIII antibody, which stained the endothelial cytoplasm positively (arrow).
(D) Immunohistochemical staining of pig graft with rabbit anti-human Factor VIII antibody, which did not stain endothelial cytoplasm.
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length and the thickness of thrombus with the same ruler.
RESULTS
The histopathological findings with regard to the xeno-
graft, which was processed as described above in the de-en-
dothelialization method, indicated the construction of an
acceptable acellular matrix, as shown in Fig. 2.
All of the experimental animals showed normal growth
patterns during each scheduled period after operation, with-
out antibiotics (except at the beginning of induction and at
the end of operation), anticoagulants, or immunosuppressants.
We compared the degrees of re-endothelialization, inflam-
mation, thrombus formation, and calcification via histopa-
thologic examinations after operation.
Re-endothelialization
All of the cases in the acellular group exhibited re-endothe-
Fig. 2. Cellular matrix (Control, A, B) and acellular matrix (C, D); Cellular matrix (A, B) showed many cellular materials and stained nuclei,
but acellular matrix (C, D) did not contain any cellular materials and showed collagen fibers only. (A) Cellular matrix (control group, hema-
toxylin and eosin stain, ×100). (B) Cellular matrix (control group , EM, ×10,000). (C) Acellular matrix (acellular group, hematoxylin and eosin
stain, ×200). (D) Acellular matrix (acellular group, EM, ×8,000).
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lialization, but none of the control group did. The degrees to
which re-endothelialization occurred also positively correlated
with the postoperative growth. Although many authors have
reported some differences, they uniformly state that the recip-
ient’s endothelium can exhibit ingrowth into any layer of the
graft (8, 11). In our study, the dog that had been sacrificed
at 12 months after operation exhibited several cells that were
penetrating into the medial layer of the xenograft (Fig. 3C).
The nuclei of the cells in the medial layer were shaped like
spindles or polygons, and proved to be positive for smooth
muscle actin immunostaining (Fig. 4). We identified these
infiltrating cells to be smooth muscle cells, which had migrat-
ed from the recipient’s aorta. It is also possible that some of
these cells maight have been fibroblasts.
Inflammation
All of the experimental animals exhibited inflammatory
reactions. The inflammatory cells were determined to have
infiltrated to more than 50% of the entire thickness of the
graft from the adventitia in the control group, and infiltrat-
ed to approximately 5-20% of the entire thickness from the
adventitia in the acellular groups (Table 2).
Thrombosis
All control group animals, upon gross examination, showed
thrombus formation. Microscopic examination showed that
the control group animals revealed thrombi of about 2,000-
Fig. 3. Immunohistochemical stain of the recipient’s endothelial
cells with rabbit anti-human Factor VIII antibody. Control group
graft did not reveal the re-endothelialization, but the entire acellular
group showed re-endothelialization and repopulation from the recip-
ient’s cells. (A) Control group did not reveal re-endothelialization 3
months after operation. (B) Recipient’s endothelial cells revealed
ingrowth into the acellular graft (arrow) 3 months after operation.
(C) Recipient’s endothelial cells showed ingrowth in the acellular
graft (arrow), and several cells were noted in the medial layer (empty
arrow) 12 months after operation.
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3,000  m thickness, and only one of the decellularized group
animals showed about 1,000  m thickness thrombus forma-
tion. Thrombus was rare in the remaining animals (Table 2).
The decellularized group animal that exhibited a 1,000  m-
thick thrombus also showed the largest size discrepancy
between the vessel diameters of the recipient and xenograft
tissues.
Calcification
The degree to which calcification occurred was less pro-
nounced in the acellular group animals than in the control
group animals (Table 2). Two of the experimental group ani-
mal revealed moderate to severe calcifications, but these ani-
mals also revealed multiple calcifications in their non-oper-
ated autologous vessels. Therefore, it was impossible to con-
fidently conclude that calcification could be caused by vas-
cular xenotransplantation. In addition, the dog that was
allowed to grow for the longest period (12 months after oper-
ation) did not show any calcification. 
DISCUSSION
Xenotransplantation is an important procedure, due to the
ease associated with graft supply. Xenotransplantation, how-
ever, has classically suffered from three primary problems.
The first problem involves immunological barriers. This
is the most important and the most difficult problem to
resolve. This problem occurs due to three distinct phenom-
ena: hyperacute rejection (HAR), acute vascular rejection
(AVR or delayed rejection), and T cell-mediated rejection.
HAR is induced by preformed antibodies in the recipient,
which bind the galactose alpha 1-3 galactose (alpha-Gal)
epitopes in the pig’s vascular endothelial cells. These bind-
ing antibodies then activate the complement, inducing graft
failure (19). Although the exact cause of AVR or delayed rejec-
tion remains elusive, the existence of preformed antibody or
Fig. 4. Immunohistochemical stain of medial layer with smooth muscle actin (SMA). (A) Recipient’s (dog) normal abdominal aorta. It showed
a regular arrangement of the normal smooth muscle cells. (B) Donor’s (pig) xenograft. The en-growing cells in the medial layer proved to be
positive for SMA immunostaining but arranged irregularly, which had migrated from the recipient’s aorta.
A B
*, Sacrificed months after operation; 
� , Involved depth from adventitia; 
� ,
% of the whole graft length; 
�, Thickness of thrombus; 
‖Severe calci-
fication shown in graft and recipient’s autologous vessel.
- Measurement conducted by a 100 scale (=1 cm) microscopic ruler.
Sacrifice* No.
Matrix
group
Re-
endo-
theliali-
zation
Adven-
titial
inflam-
mation
�
Calcifi-
cation
�
Thro-
mbus
�
1 month 1 Control No >50% 100% 3,000  m
2 Control No >50% 100% 2,000 m
3 Acellular Yes 15% Rare None
4 Acellular Yes 10% 90%
‖ None
3 months 5 Control No >50% 100% 2,500  m
6 Control No >50% 100% 3,000 m
7 Acellular Yes 20% None None
8 Acellular Yes 5% 30% None
5 months 9 Control No >50% 100% 3,000  m
10 Control No >50% 100% 2,000 m
11 Acellular Yes 5% Rare 100 m
12 Acellular Yes 20% 70%
‖ None
12 months 13 Acellular Yes 10% None 350  m
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the return of removed antibodies is known as the cause of this
form of xenograft rejection (20). T cell-mediated rejection
can also cause problems during xenotransplantation, espe-
cially during the first week after the transplantation. The
degree to which rejection occurs when a cadaveric xenograft
is used (21), however, cannot be precisely defined.
In order to prevent immunologic problems, many authors
have proposed the inactivation of the primary complement
factors, control of the expression of the complement activa-
tion regulator, the removal of anti-xenograft antibodies, mul-
tiple drugs that decrease the amount of anti-Gal antibody
secreting cells, immunosuppressants, and so on (19, 20, 22-25).
Microbiological issues comprise the second group of prob-
lems with regard to xenotransplantation. Complete eradica-
tion of exogenous viral infection and removal of endogenous
retrovirus, however, has been reported (26).
The final problem associated with xenotransplantation is
the physiological barrier. This involves the consequences of
the incompatibility between porcine and human coagula-
tion factors, and results in a characteristic ‘intragraft throm-
boses’ or ‘disseminated intravascular coagulation (DIC)’. In
order to resolve or avoid these problems, many authors have
reported on the inactivation of the endothelium of the xeno-
graft (27, 28) as well as anticoagulation therapy.
In our study, we planned to develop an ideal xenograft,
which circumvents many of the barriers related to xenotrans-
plantation. Our method for constructing this ideal xenograft
involves de-endothelialization and the removal of much of
the cellular material inherent to the xenograft.
The de-endothelialization processing in our study was based
on the methods referenced by previous articles, but also had
several unique aspects. We did not use glutaraldehyde fixa-
tion to prevent the calcification of the graft (29, 30). We
treated the xenograft with 1% SDS, which remains a con-
troversial technique. We chose a 2 hr duration time for the
nuclease treatment. The above three aspects constitute the
principal differences between our method, and those in the
previous articles (7). The optimal treatment duration and
temperature selected for our study were based on several pre-
liminary experiences by the authors.
The comparison factors we selected as our foci for the mic-
roscopic study after operation included re-endothelium, the
inflammation reaction (which reflects immunological rejec-
tion), thrombus formation, and calcification. Because vessels
are not composed of unique cells, we were unable to note
any specific findings regarding immunological rejections in
the vessels. Therefore, we regarded inflammatory reactions
as markers for immunological rejections, as stated in a pre-
vious article (31). Re-endothelialization was selected as one
of our focal factors, as we had hypothesized that the ingrowth
of the recipient’s endothelium into the de-endothelialized
xenograft would result in a more immunologically durable
xenograft. Several cell types in the recipient exhibited repop-
ulation. We clearly confirmed the ingrowth of smooth mus-
cle cells from the recipient’s aorta. Thrombus formation and
calcification are other immunological rejection factors, and
can elicit graft failure (32). In all of our cases, it was necessary
to reduce the diameter of the xenografts, which may have
influenced postoperative thrombus formation.
The results of our study revealed that the re-endothelializa-
tion of the recipient’s endothelium to the xenograft occurred
in all of the experimental group animals, but not in all of the
control group animals. Other factors occurred less frequently
in the experimental group animals than in the control group
animals. 
Therefore, we conclude that the construction of xenografts
using our modified acellularization protocol may offer accept-
able outcomes as a vascular xenograft.
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